WHO WE ARE

Leading Experts in AI-Enabled Drug Discovery

Path 1901

Our mission is to build the leading AI-enabled biotech company, to reveal hidden biological mechanisms of disease and discover breakthrough drugs. By harnessing the power of causal AI, human multi-omics data, and our Gemini Digital Twins, we aim to accelerate the discovery of life-saving therapeutics to make a meaningful impact on the lives of patients.

OUR VALUES

lines v2

Innovation

We relentlessly pursue innovative solutions, pushing the boundaries of AI and biotechnology to uncover new insights into disease mechanisms and discover breakthrough drugs.

SCIENTIFIC EXCELLENCE

We maintain the highest standards of scientific rigor, employing cutting-edge technologies and methodologies to drive our research and development.

COLLABORATION

We foster a culture of collaboration, both internally and externally, working with the brightest minds in the field to accelerate progress and advance the future of medicine.

ETHICS & INTEGRITY

We uphold the highest ethical standards in all our activities, ensuring transparency, responsible data use, and adherence to regulatory guidelines.

DIVERSITY & INCLUSION

We foster an inclusive and diverse workplace where every employee feels valued, respected, and included, irrespective of their background or identity.
lines v2

OUR STORY

At Aitia, derived from the Greek word for causality, we are rapidly turning aspiration into reality through the convergence of multi-omic patient data, high-performance computing, and causal AI. We are a team of world-class AI pioneers, R&D veterans, and biotech company builders backed by top-tier healthcare investors and strategic pharma leaders.

Our core ethos revolves around fostering an inclusive culture of knowledge-sharing, cross-discipline collaboration, and innovative thinking. We are focused on pioneering solutions that have the power to reshape the drug discovery and development landscape. We aim to redefine the very essence of disease treatment to make a difference in patients’ lives.
5
1 b scaled
2 e1702045437903
lines v2

LEADERSHIP

Isabelle Caffry
Isabelle Caffry
Senior Director, Strategy & Corporate Development
Bruce Church PhD
Bruce Church, PhD
Chief Mathematics Officer and EVP, Research and Early Development
Joseph F. Donahue Chief Business Officer
JOSEPH F. DONAHUE
Chief Business Officer
Jean Michel GriesPhD
JEAN-MICHEL GRIES, PHD
President and Chief Operating Officer
Colin Hill
COLIN HILL
Chief Executive Officer and Co-Founder
Ruby Hsu
Ruby Hsu, PhD
Senior Director, Business Development
Jeanne Latourelle D.Sc
Jeanne Latourelle, D.Sc.
Senior Vice President, Precision Medicine
Kenneth Levine
Kenneth Levine
Vice President, People and Culture
Lyudmila Makowsky 2
Lyudmila Makowsky
Vice President, Finance
So Youn Shin PhD
So-Youn Shin, PhD
Senior Director, Precision Medicine
Li Wang
Li Wang, PhD
Senior Director, Precision Oncology
Jerome Windsor
Jerome Windsor
Senior Vice President, Business Development & Strategic Alliances
lines v2

BOARD OF DIRECTORS

J Maraganore
John Maraganore, PhD
Chair of Aitia Board of Directors, Venture Partner at ARCH Venture Partners, Venture Advisor at Atlas Ventures, Executive Partner at RTW Investments. Former founding CEO and Director of Alnylam
Jan Berger MD MJ e1701964477159
Jan Berger, MD, MJ
President & Chief Executive Officer, Health Intelligence Partners, Vice Chair of Aitia Board of Directors
Craig Cimini Headshot
Craig Cimini
Vice President of Strategy and Business Development & Cigna Ventures, Cigna
Rob Coppedge e1701704387897
Rob Coppedge
President and Chief Executive Officer, Echo Health Ventures
Colin Hill
Colin Hill
Chief Executive Officer and Co-Founder
Krikston Joel e1701704345696
Joel Krikston
Managing Director Venture Investments/Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund – Observer
David Miller PhD 1 1
David W. Miller, PhD
Operating Partner, GHO Capital – Observer
Samantha Palmer PhD
Samantha Palmer, PhD
Managing Director, Amgen Ventures – Observer
Tim Thompson
Timothy Thompson
Independent Director & Former Chairman and Chief Executive Officer, Aptus Health
Adrian Weller
Adrian Weller, PhD
Senior Research Fellow, University of Cambridge Programme Director, Artificial Intelligence, The Alan Turing Institute
lines v2

SCIENTIFIC ADVISORY BOARD

avatar placeholder
Name2 Aaa
Title
avatar placeholder
Lorem Bbb
Title
avatar placeholder
Name Ccc
Title
lines v1

Grow Your Drug Discovery Career with Aitia